FDA Approves Latisse, Eyelash Enhancer, Yet No Ban on BPA.
Photo by permission of Chloe Delong
The Food and Drug Administration (FDA) recently approved Latisse, which is made by Allergan to treat a condition known as hypotrichosis of the eyelashes, or in plain English, a person who does not have enough or inadequate eyelashes. According to Allergan, lush eyelashes were realized within sixteen weeks of initial treatment. Allergan is also the maker of Botox.
“LATISSE(TM) fulfills a significant and previously unmet need in the medical aesthetic marketplace with a product approved by the FDA that increases the growth of eyelashes, making them longer, thicker and darker,” said Scott Whitcup, M.D., Allergan’s Executive Vice President of Research and Development. “As the global leader in medical aesthetics, LATISSE(TM) exemplifies our continuing commitment to developing innovative treatments that are studied in well-controlled clinical trials, manufactured to pharmaceutical standards, appropriately labeled for use, and available to consumers as a prescription product,” as stated in the Company’s press release.
The active ingredient in Latisse is bimatroprost, which is responsible for the new growth of eye lashes. It is the same ingredient in one of Allergan’s other drugs, Lumigan, which is used to treat glaucoma. Doctors found that Lumigan caused their patients’ eyelashes to become lush. In clinical trials, Allergan confirmed this finding and created Latisse, which according to the Company has mild side effects.
Subscribe to My Mobile Link























